Kornimate/medical-research-clean huggingface dataset:
cohort follow-up of survivors of hospitalization for covid-19 during the 2nd wave of the epidemic in france

Conditions: Sequelae; Fibrosis; Post-COVID Syndrome; Post-traumatic Stress Disorder

Summary: from july to september 2020, in a first uncontrolled cohort study, 478 patients who were hospitalized at bicêtre hospital for covid-19 and who survived were evaluated at 4 months (publication accepted at jama). the current project aims to bring together the means to continue this work during the 2nd epidemic wave.

from 15th july to 18th september, 2020, in a first uncontrolled cohort study (multi-expertise consultation of bicêtre after covid-19, comebac), we evaluated at four months the surviving patients who were hospitalized at the bicêtre hospital for covid-19 during the 1st wave of the epidemic in france and having survived this hospitalization. this cohort included 478 patients. the article resulting from the analysis of the data collected is accepted for publication in jama. this evaluation, the aim of which was both clinical and scientific, was carried out largely thanks to human and material resources then demobilized because of the epidemic and thanks to the investment of doctors and psychologists who carried out the work in addition to their usual work. the response to the current call for projects aims to bring together the means to continue this monitoring work during the 2nd epidemic wave, while the means and staff are this time completely mobilized by the care of patients with covid-19 and other. it also aims to raise funds that will allow an in-depth analysis of the residual symptoms presented by the patients. the current project aims to continue the work started with the comebac "1st wave" cohort with: * the inclusion of patients hospitalized after the 1st wave. * an assessment of symptoms according to the sars-cov-2 variant. * a 12-month follow-up of symptomatic patients during the evaluation in comebac "1st wave".

Eligibility criteria:
for the 6-month evaluation of patients from the 2nd epidemic wave * inclusion criteria * age ≥18 years old * covid-19 defined either by a reverse transcriptase-polymerase chain reaction (rt-pcr) or by a combination of clinical signs and compatible lung ct scan * hospitalization for covid-19 after 1st july 2020 * living out of the hospital * exclusion criteria * death occurring between index hospitalization and reassessment * patient refusal * discovery of a positive rt-pcr for sars-cov-2 during hospitalization for a reason other than covid-19 * nosocomial covid-19 for the 12-month evaluation of patients from the 1st epidemic wave * inclusion criteria ◌ presence of general, cognitive, psychological and respiratory symptoms during the assessment made at 4 months in comebac "1st wave" * exclusion criteria * death occurring between the evaluation in comebac "1st wave" and the re-evaluation * patient refusal
a dose-ranging study in patients with diabetic peripheral neuropathic pain (dpnp)

Conditions: Diabetic Peripheral Neuropathic Pain

Summary: evaluation of the efficacy of lx9211 compared to placebo in reducing dpnp. please see study website: https://diabeticpainstudy.com/


Eligibility criteria:
inclusion criteria: 1. participant has given written informed consent to participate in the study in accordance with local regulations 2. adult male and female participants ≥18 years of age at the screening visit 3. body mass index ≥18.0 to ≤40.0 kilogram per meter square (kg/m\^2) at screening 4. diagnosis of type 1 diabetes mellitus (t1dm) or type 2 diabetes mellitus (t2dm) with chronic dpnp, at screening 5. pain from dpnp present for at least 6 months prior to screening 6. at the screening visit, glycosylated hemoglobin (a1c) must be ≤11%. 7. stable regimen for the treatment of t1dm or t2dm for ≥3 months prior to screening 8. willing to adhere to the prohibitions and restrictions specified in the protocol. exclusion criteria: 1. presence of other painful conditions that may confound assessment or self-evaluation of dpnp 2. history of neurolytic or neurosurgical therapy for dpnp 3. use of opioid medications for management of dpnp within the 2 months prior to the screening visit. 4. use of prescription topical analgesics (eg, capsaicin) indicated for neuropathic pain within 3 months prior to screening 5. use of nonsteroidal anti-inflammatory drugs (nsaids) less than 2 weeks prior to screening
treatment of low back pain in pregnant women : uses of drugs and other therapies

Conditions: Low Back Pain; Pregnancy Related

Summary: low back pain is a frequent clinical condition in pregnancy. drugs treatments are limited. other therapies are often used, associated or not with drugs (acupuncture, manipulative medicine, physical therapies, homeopathy). clinical studies suggest a reduction of low back pain with these therapies. the primary objective of this study is to determinate how many pregnant women use these alternative therapeutics. in a second time, we want evaluate efficiency of these therapeutics, especially in pain modification and on quality of life. our study is a declarative study on pregnant women in lorraine.


Eligibility criteria:
inclusion criteria: * pregnant women exclusion criteria: * medical history of : bifida spina, discal hernia, osteoporosis, vertebral compaction, spondylolisthesis, scoliosis ( over 30°)
optimal dose of i.v oxycodone for postoperative pain after laparoscopic colorectal surgery

Conditions: Pain

Summary: postoperative pain control is required after major abdominal surgery, including laparoscopic colorectal surgery. intravenous oxycodone is widely used for postoperative acute pain control mainly in europe. the aim of this study is to evaluate the optimal dose of intravenous oxycodone for pain control after laparoscopic colorectal surgery in korean.

oxycodone is known to be effective in pain control and has less sedative effect than morphine does. it has been described that distribution of cytochrome p450, which is associated with metabolism of oxycodone, differed between the races. proper dose of intravenous oxycodone after major abdominal surgery has not been well defined in korean. the purpose of this study is to evaluate the optimal dose of intravenous oxycodone for pain control after laparoscopic colorectal surgery in korean based on pain score and side effects.

Eligibility criteria:
inclusion criteria: * american society of anesthesiologists class 1,2 * expected surgical time between 2 - 6 hours * scheduled for laparoscopic colorectal surgery exclusion criteria: * severe dysfunction of liver, heart, kidney, or lung * cannot understand numeric rating scale of pain * known or suspected allergy to oxycodone * previous history of postoperative nausea or vomiting * medication of antidepressants * postoperative long-term icu care or prolonged mechanical ventilatory support * chronic pain * drug abuser * hypersensitivity reaction to aspirin or nsaids * refuse to enroll

Keywords: acute pain postoperative surgery
incidence of ocular antibodies in patients with sturge - weber syndrome (sws)

Conditions: Sturge - Weber Syndrome (SWS)

Summary: sturge-weber syndrome (sws) is a neurological disorder characterized at birth by seizures and a large port-wine stain birthmark on the forehead and upper eyelid of one side of the face. sws is also accompanied by an increased pressure within the eye (glaucoma) which can develop very early in life. glaucoma represents a group of ocular disorders that are characterized by the loss of retinal ganglion cells and their axons, damage to the optic nerve, and gradual loss of visual field. recently, several studies provided evidence that there is a potential role of the immune system in the pathogenesis of glaucoma. these findings suggest that there might be changes in systemic humoral immunity possibly underlying the optic neuropathy in at least some glaucoma patients.

the ocular antibody profile in patients with sws is unknown.the researchers want to study on blood and tear drop samples from patients with sws to determine the incidence of ocular antibodies in patients with this syndrome.

Eligibility criteria:
inclusion criteria: * male and female volunteers with sws of all ages exclusion criteria: * volunteers without sws
efficacy of symbicort versus its monocomponents - spruce 160/4.5

Conditions: Asthma

Summary: the purpose of this study is to compare symbicort with budesonide alone and with formoterol alone in the treatment of asthma in adolescents and adults


Eligibility criteria:
inclusion criteria: * at least 12 years of age * diagnosis of asthma * baseline lung function test results as determined by protocol and required and received treatment with inhaled corticosteroids and/or lung treatments specified in protocol within the timeframe and doses specified in the protocol exclusion criteria: * has required treatment with non-inhaled corticosteroids within previous 4 weeks, has sensitivity to drugs specified in the protocol or requires treatment with beta-blockers * had cancer within previous 5 years or currently has any other significant disease or disorder as judged by the investigator

Keywords: asthma symbicort budesonide/formoterol budesonide formoterol
small steps for big changes: a lifestyle program to reduce the risk of developing type 2 diabetes

Conditions: PreDiabetes

Summary: the purpose of this study is to address whether inactive individuals with prediabetes who take part in the small steps for big changes program, which is a 3-week supervised exercise and lifestyle change program with brief counseling, will be more adherent to regular exercise one year after program completion compared to before they took part in the program.

the study is a one-group repeated measures design and the primary outcome is exercise adherence at 12 months post the 3-week supervised exercise program. there is no randomization of individuals to conditions. exercise adherence will be measured using self-report physical activity (using the godin leisure time exercise questionnaire) and a subsample will also wear tri-axial accelerometers to measure total time spent in moderate-to-vigorous physical activity assessed over 7 days. secondary outcomes include physical fitness, haemoglobin a1c, quality of life, self-regulatory efficacy, anthropometrics, diet and exercise-related cognitive errors. the 3-week lifestyle program includes six sessions with a lifestyle coach and exercise sessions performed at home. these sessions will focus on regular healthy lifestyle that includes walking (or exercise of any kind) at least three times per week and will highlight simple dietary strategies that are linked to reduced risk of t2d. the 3-week supervised exercise program includes brief exercise counseling sessions that teach participants self-regulatory skills to promote independence and long-term adherence to exercise and a healthy diet. at the conclusion of the three-week program, participants will be asked to continue exercising a minimum of three times per week for twelve months on their own.

Eligibility criteria:
inclusion criteria: * ability to speak and read english * bmi between 25-40 kg/m2 (as measured by body mass and height self-reporting), * blood pressure of \<160/99 mm hg assessed according to chep guidelines, * not diagnosed with type 2 diabetes * no prior history of cardiovascular disease * not on hormone replacement therapy * cardiovascular medications (e.g., statins) will be allowed if the participant is on stable therapy (6 months on same dose). exclusion criteria, if subjects: * take glucose-lowering medications that have changed within the past 6 months; * report any explicit contraindications to exercise (e.g., musculoskeletal injury, chest pain during exercise) * report having had a heart attack or stroke in the past; * report that they are pregnant or plan on becoming pregnant over the next 12 months; * have uncontrolled major depression; * have bone or joint problem (for example, back, knee, or hip) that could be made worse by a change in physical activity which a physician has not cleared them for to exercise; * report that a physician has not cleared their participant for exercise.

Keywords: prediabetes, lifestyle intervention, exercise behavior, adherence
basic body awareness therapy (bbat) for patients with chronic obstructive pulmonary disease

Conditions: Chronic Obstructive Pulmonary Disease

Summary: chronic obstructive pulmonary disease (copd) is a burden to health care and economic systems globally, to manage this preventable and treatable disease, different pharmacological and non-pharmacological interventions were shown to be effective. chronic and progressive dyspnea, cough and sputum production are the characteristic symptoms of copd. the most commonly encountered symptom in patients with copd is dyspnea, it is a subjective experience of breathing discomfort . it causes impact on patient's health status, sleep quality, anxiety and depression level. therefore, skills transfer in self-managing major symptoms are crucial to prevent negative consequences, and as suggested by global initiative for chronic obstructive lung disease (gold), managing symptoms and to prevent future risk of exacerbations is important for stable copd cases. basic body awareness therapy (bbat) is a physio-therapeutic intervention directed toward patients' functional movement quality. the development of bbat was based on the hypothesis of persons' lacking contact with and lacking awareness on their own body, with their inner life, external environment and in the relation to other persons. thus, it leads to dysfunctional movement, pain and other body functions. bbat focus on multi-perspective within a person including physical, physiological, psycho-social-cultural and existential perspectives. it directs patients to be "aware", guides patients to have mental contact with their body, monitors internal sensations and external environment, and thus, to enhance the self-regulated behavior and positive emotional state. there are three key components in practicing bbat, namely balance, free breathing and mental awareness. evidence shown that the effect of bbat is significant in improving physical and psycho-social well-being in patients with different physical and mental disorders. now, there is absence of evidence in applying bbat in managing cases with respiratory diseases, especially for those with prominent symptoms of dyspnea (for example copd cases). the objectives of this study are (1) to evaluate individual bbat as an add-on treatment in patients with copd, (2) to understand copd patients' experience through participating in individual basic body awareness therapy (bbat).


Eligibility criteria:
inclusion criteria: * patients diagnosed with copd (icd-9-cm 496.x) and * ability to stand independently without aids, and * subjectively experienced dyspnea, and * ability to listen, speak, read and understand chinese. exclusion criteria: * patients with acute exacerbation of copd within one-month, or * patients with medical disorders possibly causing dyspnea (for example asthma, heart failure, etc.), or * patients with major psychiatric or cognitive disorders, or * patients refusal

Keywords: basic body awareness therapy chronic obstructive pulmonary disease dyspnea self-management physiotherapy
exploratory clinical study of penpulimab combined with sox in the perioperative treatment of gastric cancer

Conditions: Gastric Cancer

Summary: to explore the efficacy and safety of penpulimab combined with sox in the perioperative treatment of gastric cancer

gastric cancer is one of the malignant tumors that seriously threaten human health. it is the sixth most common malignant tumor in the world. according to global cancer statistics 2020, there were about 1.089 million new cases of gastric cancer and 768,000 deaths of gastric cancer worldwide in 2020. multidisciplinary treatment with radical surgical resection as the core is the mainstream mode of comprehensive treatment of gastric cancer at present, and radical gastrectomy is recognized as the best treatment. however, for patients with advanced gastric cancer, the effect of surgery alone is not good, and the postoperative tumor recurrence rate is high. in order to improve the disease-free survival rate and overall surv ival (os) rate of gastric cancer patients after surgery, perioperative comprehensive therapy has been gradually adopted by the majority of scholars, and has achieved encouraging efficacy in clinical application.

Eligibility criteria:
inclusion criteria: * signed and dated informed consent; * at least 18 years of age; * ecog ps: 0-1; * patients with gastric cancer diagnosed as t3-4nxmx by imaging; * patients with gastric adenocarcinoma diagnosed by cytology; * patients with gastric cancer assessed by the surgeon as suitable for neoadjuvant therapy or conversion therapy followed by radical resection; * laboratory tests should meet the following requirements (28 days before enrollment in baseline period) : * women should agree that they must use contraception during and for 6 months after the study; had a negative serum pregnancy test within 7 days prior to study enrollment and had to be non-lactating; men should agree that they must use contraception during the study and for 6 months after the end of the study period. exclusion criteria: * co-existing with other malignant tumors (except cured basal cell carcinoma of the skin); * gastric cancer patients with t1-2n0m0; * previous treatment including anti-pd-1 /pd-l1/ctla-4 antibody therapy or other immunotherapy directed against pd-1/pd-l1/ctla-4; * weight loss greater than or equal to 20% within 4 weeks before the first dose; * severe hypersensitivity after administration of other monoclonal antibodies; * the presence or history of any active autoimmune disease * immunosuppressive therapy, systemic or absorbable local hormone therapy (dose \> 10mg/ day prednisone or other effective hormone) is required to achieve immunosuppression and continues to be used within 2 weeks of the first administration; * patients with multiple factors affecting oral medication * uncontrolled pleural effusion, pericardial effusion, or ascites that require repeated drainage; * had received a prophylactic or attenuated vaccine within 4 weeks before the first dose;

Keywords: gastric cancer, sox, pd-1, perioperative period
a human trial to evaluate the efficacy and safety of aged garlic powder on improvement of blood lipids in subjects with hyperlipidemia

Conditions: Hyperlipidemia

Summary: we performed a double-blind parallel study in a group of mildly hypercholesterolemic subjects who were given aged garlic powder over a period of 12 weeks. we measured serum lipids, including total cholesterol, low-density-lipoprotein (ldl) and high-density-lipoprotein (hdl) cholesterol, and triglycerides, and monitored their blood pressure.

an increased serum cholesterol level is an important risk factor for the development of cardiovascular and cerebrovascular disease. reduction of these and other risk factors through dietary modification, behavioral changes, and medicinal intervention has already substantially decreased the incidence and mortality from cardiovascular and cerebrovascular disease. supplementation of the diet with certain biofactors may further reduce such risk factors. aged garlic belongs to a group of dietary supplements that may lessen the incidence of cardiovascular and cerebrovascular disease by reducing lipids levels and decreasing platelet responsiveness to activating agents.

Eligibility criteria:
inclusion criteria: * mild hypercholesterolemic subjects aged from 20 to 80 years * had no received lipid-lowering drugs for at least 3 months prior to the recruitment exclusion criteria: * self-reported pregnancy,lactation * prevalent heart disease,cancer,renal disorder, or diabetes mellitus, and use of lipid or antihypertensive medications

Keywords: aged garlic hyperlipidemic ldl hdl triglyceride
radiation therapy in treating older women who are undergoing surgery for stage i or stage ii breast cancer

Conditions: Breast Cancer

Summary: rationale: radiation therapy uses high-energy x rays to kill tumor cells. giving radiation therapy after surgery may kill any tumor cells that remain after surgery. purpose: this phase ii trial is studying how well radiation therapy works in treating older women who are undergoing surgery for stage i or stage ii breast cancer.

objectives: primary * determine reproducibility of localized and concentrated adjuvant radiotherapy, in terms of isodose curve and dose heterogeneity, in older women with stage i or ii breast cancer. secondary * determine the impact of this regimen on katz's activity of daily living score and lawton's instrumental activity of daily living score in these patients. * determine relapse-free survival of patients treated with this regimen. * determine overall and specific survival of patients treated with this regimen. * determine the cosmetic result, as assessed by the patient, surgeon, and radiologist, of this regimen in these patients. * determine the direct and indirect costs of this regimen in these patients. outline: this is a multicenter, open-label, nonrandomized study. patients undergo surgery. after surgery, patients undergo radiotherapy twice daily for 5 days. projected accrual: a total of 42 patients will be accrued for this study.

Eligibility criteria:
disease characteristics: * diagnosis of invasive breast cancer * stage i or ii disease * tumor size ≤ 30 mm * located in any breast quadrant * no nodal involvement * no inflammatory breast cancer * no positive margins after surgical resection (performed on study) * no microcalcifications * hormone receptor status * not specified patient characteristics: age * over 70 sex * female menopausal status * not specified performance status * karnofsky 70-100% life expectancy * not specified hematopoietic * not specified hepatic * not specified renal * not specified prior concurrent therapy: biologic therapy * not specified chemotherapy * not specified endocrine therapy * not specified radiotherapy * not specified surgery * not specified

Keywords: stage i breast cancer stage ii breast cancer
influence of gemcitabine treatment on immunological and serological profile in patients with pancreatic cancer

Conditions: Pancreatic Tubular Adenocarcinoma

Summary: observational study of influence of gemcitabine treatment on serological and immunological status and gene expression profile in patients with pancreatic tubular carcinoma after tumor resection.


Eligibility criteria:
inclusion criteria: * ecog performance status 0-2 at the time of inclusion * following r0 or r1 pancreatic tubular adenocarcinoma resection exclusion criteria: * pregnancy * serious comorbidity

Keywords: pancreatic tubular adenocarcinoma gemcitabine gene expression immunological status serological status pancreatic tubular adenocarcinoma adjuvant setting
a trial of alimta (pemetrexed) plus irinotecan in patients who have been previously treated for metastatic colorectal cancer.

Conditions: Colorectal Cancer

Summary: this is a non-randomized study in patients who have received prior 5-fu therapy for colorectal cancer. the objective of this trial is to establish a maximum tolerated dose of alimta and irinotecan given in combination as well as to assess the safety and efficacy of this combination for patients with locally advanced or metastatic colorectal cancer. alimta and irinotecan will be given every 21 days.


Eligibility criteria:
inclusion criteria: * histologic or cytologic diagnosis of locally or metastatic colorectal cancer * prior therapy with 5-fu for metastatic cancer * adequate bone marrow, liver and kidney function exclusion criteria: * pregnancy * breast feeding * inability to interrupt aspirin therapy * brain metastasis * patients who have been treated previously with alimta or irinotecan